Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Escalon Medical (ESMC) Risk Analysis

Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). Risk factors show the challenges a company faces. Investors can consider the worst-case scenarios before making an investment. TipRanks’ Risk Analysis categorizes risks based on proprietary classification algorithms and machine learning. Escalon Medical disclosed 20 risk factors in its most recent earnings report. Escalon Medical reported the most risks in the “Finance & Corporate” category.

Risk Overview Q2, 2026

Source: the company's latest filing for the period ended Jun 30, 2026, filed Oct 13, 2026

Risk Distribution
20Risks
Sector Avg.Finance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Risk Change Over Time

Escalon Medical disclosed risks per quarterNo. of Risks19.752020.2520.520.752121.25Q3Q4Q12023Q2Q3Q4Q12024Q2Q3Q4Q12025Q2Q3Q2Showing: Q2, 2026
Risks removedRisks addedRisks changedEscalon Medical Risk Factors
  • Capital Markets - Risk 1
    Tariffs and International Trade Policies

    The Company's business may be adversely affected by changes in tariffs, trade policies, import duties, or other governmental actions affecting the products and components we purchase from foreign suppliers. Increases in tariffs or the imposition of new trade restrictions could increase our cost of goods sold, reduce gross margins, disrupt our supply chain, or require us to seek alternative suppliers, which may not be available on favorable terms or within required timeframes. Although we may seek to mitigate the impact of higher costs through pricing adjustments, supplier negotiations, or sourcing alternatives, there can be no assurance that such measures will fully offset the effects of increased tariffs or trade restrictions. Any significant increase in costs or disruption in the availability of products or components could adversely affect our operating results, cash flows, and financial condition.

Read and Evaluate the RiskReserved for Ultimate MembersUpgrade

Risk Highlights Q2, 2026

Main Risk Category
Finance & Corporate
With 6 Risks
Number of Disclosed Risks
20
No changes from last report
S&P 500 Average: 32
Recent Changes
1Risks added
1Risks removed
0Risks changed
Since Jun 2026
Number of Risk Changed
0
No changes from last report
S&P 500 Average: 1

Risk Word Cloud

the company's results fluctuate from quarter to quarter.quarter to quarterthere are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with united states gaap. any changes in estimates, judgments and assumptions used could have a material adverse effect on the company's business, financial position and operating results.preparation of financial statementsthe company is dependent on its management and key personnel to succeed.key personnel to succeedthe company's international operations could be adversely impacted by changes in laws or policies of foreign governmental agencies and social and economic conditions in the countries in which the company operates.policies of foreign governmental agenciesthe company's products are subject to stringent ongoing regulation by the fda and similar domestic and foreign health care regulatory authorities, and if the regulatory approvals or clearances of the company's products are restricted or revoked, the company could face delays that would impair the company's ability to generate funds from operations.foreign health care regulatory authoritieshealthcare policy changes, including pending proposals to reform the u.s. healthcare system and implementation of the affordable healthcare act, may have a material adverse effect on the company.including pending proposals to reformthe company's chairman and chief executive officer, richard depiano jr. is the company's controlling stockholder and has sufficient voting power to determine the outcome of all matters submitted to the company's stockholders for approval.sufficient voting power to determinethe company's products are subject to stringent ongoing regulation by the fda and similar domestic and foreign health care regulatory authorities, and if the regulatory approvals or clearances of the company's products are restricted or revoked, the company could face delays that would impair the company's ability to generate funds from operations.subject to stringent ongoing regulationthe company's products are subject to stringent ongoing regulation by the fda and similar domestic and foreign health care regulatory authorities, and if the regulatory approvals or clearances of the company's products are restricted or revoked, the company could face delays that would impair the company's ability to generate funds from operations.ability to generate fundsthe company's products employ proprietary technology, and this technology may infringe on the intellectual property rights of third parties.products employ proprietary technology

Risk Factors Full Breakdown - Total Risks 20

Share Price & Shareholder Rights3 | 15.0%
  • Share Price & Shareholder Rights - Risk 1
    The Company's charter documents and Pennsylvania law may inhibit a takeover.

    Certain provisions of Pennsylvania law and the Company's Bylaws could delay or impede the removal of incumbent directors and could make it more difficult for a third party to acquire, or discourage a third party from attempting to acquire, control of the Company. These provisions could limit the share price that certain investors might be willing to pay in the future for shares of the Company's common stock. The Company's Board of Directors is divided into three classes, with directors in each class elected for three-year terms. The Bylaws impose various procedural and other requirements that could make it more difficult for stockholders to effect certain corporate actions. The Company's Board of Directors may issue shares of preferred stock without stockholder approval on such terms and conditions, and having such rights, privileges and preferences, as the Board may determine. The rights of the holders of common stock will be subject to, and may be adversely impacted by, the rights of the holders of any preferred stock that may be issued in the future.

  • Share Price & Shareholder Rights - Risk 2
    The Company's Chairman and Chief Executive Officer, Richard DePiano Jr. is the Company's controlling stockholder and has sufficient voting power to determine the outcome of all matters submitted to the Company's stockholders for approval.

    In February 2018, the Company entered into a Debt Exchange Agreement (the "Exchange Agreement") with Mr. DePiano Sr. and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the "Holders"). Pursuant to the terms of the Exchange Agreement, the Holders exchanged a total of $645,000 principal amount of debt the Company owed the Holders under factoring agreements and notes (the "Notes") the Company entered into with the Holders in February and March of 2016 for 2,000,000 shares of Series A Convertible Preferred Stock (the "Preferred Stock"). Each share of the Preferred Stock entitles the holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company's stockholders. As a result of this voting power, the holders currently beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company's stockholders. If the holders were to convert their shares of Preferred Stock into common stock at the current conversion ratio, the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the currently outstanding shares of Common Stock assuming such conversion. The holders, therefore, control the election of all of the members of the Company's board of directors and control the outcome of any corporate transaction or other matter submitted to a vote of the Company's stockholders for approval, including mergers or other acquisition proposals and the sale of all or substantially all of the Company's assets, in each case regardless of how all of the Company's stockholders other than the holders vote their shares. The interests of the Holders in maintaining this voting control of the Company may have an adverse effect on the price of the Company's common stock because of the absence of any potential "takeover" premium and may, therefore, be inconsistent with the interest of the Company's stockholders other than the holders. The voting control by the holders could also discourage a third party from attempting to acquire control of the Company and may make it more difficult for a third party to acquire control of the Company. Mr. DePiano Sr. passed away on October 3, 2019 and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the shares in his capacity as executor of Mr. DePiano Sr.'s estate.

  • Share Price & Shareholder Rights - Risk 3
    The market price of the Company's stock has historically been volatile, and the Company has not paid cash dividends.

    The volatility of the Company's common stock imposes a greater risk of capital losses on stockholders as compared to less volatile stocks. In addition, such volatility makes it difficult to ascribe a stable valuation to a stockholder's holdings of the Company's common stock. The following factors have and may continue to have a significant impact on the market price of the Company's common stock: - Acquisitions, strategic alliances, joint ventures and divestitures that the Company effects, if any;- Announcements of technological innovations;- Changes in marketing, product pricing and sales strategies or new products by the Company's competitors;- Changes in domestic or foreign governmental regulations or regulatory requirements; and - Developments or disputes relating to patent or proprietary rights and public concern as to the safety and efficacy of the procedures for which the Company's products are used. Moreover, the possibility exists that the stock market could experience extreme price and volume fluctuations unrelated to operating performance. The Company has not paid cash dividends on its common stock and does not anticipate paying cash dividends in the foreseeable future. If the Company raises funds in the future, the Company may be required to raise those funds through public or private financings, strategic relationships or other arrangements at prices and other terms that may not be favorable. The sale of additional equity and debt securities may result in additional dilution to the Company's stockholders. Additional financing may not be available in amounts or on terms acceptable to the Company or at all.

Accounting & Financial Operations2 | 10.0%
Corporate Activity and Growth1 | 5.0%

See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

FAQ

What are “Risk Factors”?
Risk factors are any situations or occurrences that could make investing in a company risky. The Securities and Exchange Commission (SEC) requires that publicly traded companies disclose their most significant risk factors. This is so that potential investors can consider any risks before they make an investment. They also offer companies protection, as a company can use risk factors as liability protection. This could happen if a company underperforms and investors take legal action as a result. It is worth noting that smaller companies, that is those with a public float of under $75 million on the last business day, do not have to include risk factors in their 10-K and 10-Q forms, although some may choose to do so.
How do companies disclose their risk factors?
Publicly traded companies initially disclose their risk factors to the SEC through their S-1 filings as part of the IPO process. Additionally, companies must provide a complete list of risk factors in their Annual Reports (Form 10-K) or (Form 20-F) for “foreign private issuers”. Quarterly Reports also include a section on risk factors (Form 10-Q) where companies are only required to update any changes since the previous report. According to the SEC, risk factors should be reported concisely, logically and in “plain English” so investors can understand them.
How can I use TipRanks risk factors in my stock research?
Use the Risk Factors tab to get data about the risk factors of any company in which you are considering investing. You can easily see the most significant risks a company is facing. Additionally, you can find out which risk factors a company has added, removed or adjusted since its previous disclosure. You can also see how a company’s risk factors compare to others in its sector. Without reading company reports or participating in conference calls, you would most likely not have access to this sort of information, which is usually not included in press releases or other public announcements. A simplified analysis of risk factors is unique to TipRanks.
What are all the risk factor categories?
TipRanks has identified 6 major categories of risk factors and a number of subcategories for each. You can see how these categories are broken down in the list below. 1. Financial & Corporate Accounting & Financial Operations - risks related to accounting loss, value of intangible assets, financial statements, value of intangible assets, financial reporting, estimates, guidance, company profitability, dividends, fluctuating results. Share Price & Shareholder Rights – risks related to things that impact share prices and the rights of shareholders, including analyst ratings, major shareholder activity, trade volatility, liquidity of shares, anti-takeover provisions, international listing, dual listing. Debt & Financing – risks related to debt, funding, financing and interest rates, financial investments. Corporate Activity and Growth – risks related to restructuring, M&As, joint ventures, execution of corporate strategy, strategic alliances. 2. Legal & Regulatory Litigation and Legal Liabilities – risks related to litigation/ lawsuits against the company. Regulation – risks related to compliance, GDPR, and new legislation. Environmental / Social – risks related to environmental regulation and to data privacy. Taxation & Government Incentives – risks related to taxation and changes in government incentives. 3. Production Costs – risks related to costs of production including commodity prices, future contracts, inventory. Supply Chain – risks related to the company’s suppliers. Manufacturing – risks related to the company’s manufacturing process including product quality and product recalls. Human Capital – risks related to recruitment, training and retention of key employees, employee relationships & unions labor disputes, pension, and post retirement benefits, medical, health and welfare benefits, employee misconduct, employee litigation. 4. Technology & Innovation Innovation / R&D – risks related to innovation and new product development. Technology – risks related to the company’s reliance on technology. Cyber Security – risks related to securing the company’s digital assets and from cyber attacks. Trade Secrets & Patents – risks related to the company’s ability to protect its intellectual property and to infringement claims against the company as well as piracy and unlicensed copying. 5. Ability to Sell Demand – risks related to the demand of the company’s goods and services including seasonality, reliance on key customers. Competition – risks related to the company’s competition including substitutes. Sales & Marketing – risks related to sales, marketing, and distribution channels, pricing, and market penetration. Brand & Reputation – risks related to the company’s brand and reputation. 6. Macro & Political Economy & Political Environment – risks related to changes in economic and political conditions. Natural and Human Disruptions – risks related to catastrophes, floods, storms, terror, earthquakes, coronavirus pandemic/COVID-19. International Operations – risks related to the global nature of the company. Capital Markets – risks related to exchange rates and trade, cryptocurrency.